Arbutus Biopharma Corporation
ABUS
$3.25
-$0.265-7.55%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.57M | 1.34M | 1.73M | 1.53M | 2.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.57M | 1.34M | 1.73M | 1.53M | 2.15M |
| Cost of Revenue | 8.81M | 14.27M | 15.55M | 15.40M | 17.56M |
| Gross Profit | -7.24M | -12.93M | -13.83M | -13.87M | -15.42M |
| SG&A Expenses | 8.43M | 4.54M | 7.55M | 5.31M | 5.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.24M | 18.81M | 23.10M | 20.72M | 22.67M |
| Operating Income | -15.67M | -17.47M | -21.37M | -19.18M | -20.52M |
| Income Before Tax | -12.53M | -19.72M | -19.80M | -17.88M | -19.31M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.53M | -19.72M | -19.80M | -17.88M | -19.31M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.53M | -19.72M | -19.80M | -17.88M | -19.31M |
| EBIT | -15.67M | -17.47M | -21.37M | -19.18M | -20.52M |
| EBITDA | -15.34M | -17.14M | -21.02M | -18.83M | -20.16M |
| EPS Basic | -0.07 | -0.10 | -0.11 | -0.10 | -0.11 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.07 | -0.06 | -0.07 |
| EPS Diluted | -0.07 | -0.10 | -0.11 | -0.10 | -0.12 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.07 | -0.06 | -0.07 |
| Average Basic Shares Outstanding | 189.70M | 189.00M | 188.04M | 175.63M | 168.59M |
| Average Diluted Shares Outstanding | 189.70M | 189.00M | 188.04M | 175.63M | 168.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
